<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01959555</url>
  </required_header>
  <id_info>
    <org_study_id>HAEM-4076</org_study_id>
    <secondary_id>U1111-1136-7052</secondary_id>
    <secondary_id>NOV-HEM-2013-01</secondary_id>
    <nct_id>NCT01959555</nct_id>
  </id_info>
  <brief_title>Project to Update the Study of Congenital Haemophilia in Spain</brief_title>
  <acronym>PUCHS</acronym>
  <official_title>Project to Update the Study of Congenital Haemophilia in Spain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Europe. The aim of the study is to update the knowledge about the
      prevalence and severity of congenital haemophilia (A and B) in Spain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of congenital haemophilia A and B in Spain in 2013, described as proportion (%) of patients in the total population (extracted from the last available census of the Spanish population for the regions considered for the study)</measure>
    <time_frame>Assessed at study visit (day 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity (mild, moderate or severe) of congenital haemophilia A and B in Spain during 2013, described as proportion (%) per category of the total number of patients with haemophilia A or B</measure>
    <time_frame>Assessed at study visit (day 1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean current age at the time of visit to the HTC in 2013</measure>
    <time_frame>Assessed at study visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean age at diagnosis</measure>
    <time_frame>Assessed at study visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion (%) of patients with/without genetic screening performed</measure>
    <time_frame>Assessed at study visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion (%) of patients who needed support of a reference Haemophilia Healthcare Centre in 2013</measure>
    <time_frame>Assessed at study visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion (%) of patients who received plasmatic or recombinant treatment</measure>
    <time_frame>Assessed at study visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion (%) of patients who received on demand or prophylaxis treatment</measure>
    <time_frame>Assessed at study visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of bleeding episodes</measure>
    <time_frame>Assessed at study visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of joint bleeds</measure>
    <time_frame>Assessed at study visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion (%) of patients with established arthropathy</measure>
    <time_frame>Assessed at study visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion (%) of patients with infectious complications</measure>
    <time_frame>Assessed at study visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion (%) of patients with HIV (Human immunodeficiency virus)</measure>
    <time_frame>Assessed at study visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion (%) of patients with presence of inhibitors</measure>
    <time_frame>Assessed at study visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion (%) of patients with immune tolerance induction treatment performed</measure>
    <time_frame>Assessed at study visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of surgery interventions performed</measure>
    <time_frame>ThAssessed at study visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion (%) of patients with quality of life questionnaire (QoLQ) performed in 2013</measure>
    <time_frame>Assessed at study visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of days of absenteeism to school/university in children and adolescents in 2013</measure>
    <time_frame>Assessed at study visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of days of absenteeism from work in 2013</measure>
    <time_frame>Assessed at study visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion (%) of patients with treatment administered at home</measure>
    <time_frame>Assessed at study visit (day 1)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1157</enrollment>
  <condition>Congenital Bleeding Disorder</condition>
  <condition>Haemophilia A</condition>
  <condition>Haemophilia B</condition>
  <arm_group>
    <arm_group_label>Retrospective collection of data</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment given</intervention_name>
    <description>Patients will not be treated with any specific product. Data collection only.</description>
    <arm_group_label>Retrospective collection of data</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in active follow-up in HTCs (Haemophilia Treatment Centres) will be included in
        this study. A patient is considered as active if a visit to the HTC is performed in the
        period of January 2013 to December 2013.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained before any study-related activities. (Study-related
             activities are any procedure related to recording of data according to the protocol)

          -  Male patients of any age diagnosed with congenital haemophilia A or B who visited
             their HTC at least once during the period of January 2013 to December 2013

        Exclusion Criteria:

          -  Previous participation in this study

          -  Female patients

          -  Acquired haemophilia
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <last_update_submitted>November 27, 2015</last_update_submitted>
  <last_update_submitted_qc>November 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

